Why the genomic revolution needs tools beyond just sequencing — and how Bionano is in a league of its own
8
6
Beyond handwaving explanations why labs are unprofitable — and what it means for the clinical genomics workforce
15
Part 1 — Bull case on Invitae and how genomic testing could become a winner-take-most industry
11
1
Part 1 — A high-level overview of the bull and bear case on Ginkgo and how we got here
6
9
How MaxCyte makes revenue from cell-therapy companies like CRISPR Therapeutics, Editas, and Caribou's R&D expenses
7
4
Part 2 — Taking a closer look at Ginkgo's biofoundry, specific products they've designed, and the value of a horizontal model
5
6
Why dystopian science fiction fails to capture the wonders of biology
10
7
It's been a painful yet formative year. Looking back before looking ahead
8
3
How DNA synthesis powers the infrastructure for writing biology
5
3
How Senseonics and Nemaura Medical can make a big dent in the continuous glucose monitoring market
4
Part 2 — Exploring Twist Bioscience’s competition and defensibility
6
Napkin math valuation estimates for Invitae in 2022 — in search of a 10x investment
4